| abstract |
Disclosed herein are formulations and site-specific methods of administration of Compound (I) or a pharmaceutically acceptable salt thereof. Compound (I) is a potent BTK inhibitor and therefore useful in the treatment of diseases such as cancer, autoimmune diseases and inflammatory diseases. |